News | June 04, 2026
Novo Nordisk launches Wegovy pill in UAE in first global rollout outside US
The move signals a major expansion in access to next-generation weight-loss therapies
The move signals a major expansion in access to next-generation weight-loss therapies
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
The filing is backed by Phase III data from the lidERA Breast Cancer study
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The approval is supported by results from the Phase 3 SWOG 1826 trial
Subscribe To Our Newsletter & Stay Updated
